google-plus2 facebook < /path> twitter blogger tumblr2 reddit linkedin delicious stumbleupon mail

Related articles: Preventing the Marketing of Unproven Stem Cell Treatments

June, 2018: ISSCR Writes to Canadian Minister of Health Regarding Health Canada's Guidance on the Regulation of Cell Therapy Products

May, 2018: ISSCR Applauds Federal Injunctions Against Stem Cell Clinics

May, 2018: ISSCR Writes to Department of Health, Drug Office of Hong Kong Regarding Department of Health's Consultation Document for the Regulation of Advanced Therapy Products

May, 2018: ISSCR Writes to the Drugs Controller General of India Regarding Regulation of Stem Cell and Cell-based Products

March, 2018: ISSCR Writes to Australian Therapeutic Goods Administration Regarding Regulations for Autologous Cell and Tissue Products
 
November, 2017: ISSCR Applauds the FDA Announcement of New Guidelines for Cellular Therapies and Cell-based Tissue Products

October, 2017: ISSCR Applauds California Bill to Assist Stem Cell Patients

August, 2017: ISSCR Responds to FDA Announcement of Enforcement Direction for Stem Cell Treatments

July, 2017: ISSCR Endorses California Senate Bill 512

June, 2017: Letter to India Secretary of Department of Biotechnology Regarding Unproven Therapy Clinics in India

December, 2016: ISSCR Comments on 21st Century Cures Act in U.S.

November, 2016: ISSCR Comments to Australian Therapeutic Goods Administration on Regulation of Autologous Cell and Tissue Products

"Right to Try" Legislation

March, 2018: Letter from ISSCR to Leadership of U.S. House of Representatives Opposing Right to Try

February, 2018: Letter from ISSCR and Patient Organizations to U.S. House of Representatives Leadership  

August, 2017: Letter to U.S. House of Representatives Energy & Commerce Committee

June, 2017: Letter to Massachusetts Legislature Regarding "Right to Try" Legislation

May, 2017: Letter to Texas House of Representatives, U.S., Opposing Legislation It Says Would Put Patients at Risk